

## Zuberitamab

Cat. No.:	HY-P99501
CAS No.:	2251143-19-6
Target:	CD20
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma <sup>[1]</sup> .
<b>In Vivo</b>	Zuberitamab (0.1 mg/kg, intravenous injection, on day 0 and 10, 2 weeks) alone has no or minimal effect on tumor growth, when combined with BR105 results in significant inhibition of tumor growth with good anti-tumor efficacy in IRP $\alpha$ -humanized B-NDG mice tumor xenograft model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Zhen-Hua Wu, et al. Preclinical characterization of the novel anti-SIRP $\alpha$  antibody BR105 that targets the myeloid immune checkpoint. J Immunother Cancer. 2022 Mar;10(3):e004054.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA